European pharma strategy report approved with huge majority

A report constituting the EU Parliament's contribution to the Commission's upcoming pharmaceutical legislation was adopted on Wednesday.

Photo: AJ Vaccines

BRUSSELS – The reduction to the lifetime of pharmaceutical patents has come one step closer to having a permanent place in European law.

On Wednesday, the EU Parliament approved the report that forms the basis of the strategy text with a significant majority, with 527 votes for the strategy out of a possible 689.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs